Company: ZVRA
Filing Date: 2025-04-16
Form Type: PRRN14A
Source: 0000897069-25-000815
Chunk: 30

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-16
Form: PRRN14A
Chunk 30
---
000, in accordance with Item 404(a) of Regulation S-K; (4) the identification of any Section 16 insider who failed to file a timely report under Section 16 in the last fiscal year, along with any required information, in accordance with Item 405 of Regulation S-K; (5) the information regarding the audit committee and audit committee matters required by Item 407(d)(4), (d)(5) and (h) of Regulation S-K under the Exchange Act; (6) information regarding the compensation of directors and executive officers, in accordance with Item 402 of Regulation S-K; (7) the information regarding the compensation committee and compensation committee matters required by Item 407(e)(4) and (e)(5) of Regulation S-K; (8) the information regarding independent public accountants required by Item 9 of Schedule 14A; (9) the information regarding delivery of documents to security holders sharing an address required by Item 23 of Schedule 14A; (10) the information regarding shareholder approval of executive compensation required by Item 24 of Schedule 14A; and (11) the information required by Item 25 of Schedule 14A. STOCKHOLDERS ARE DIRECTED TO REFER TO THE COMPANY’S PROXY STATEMENT FOR THE FOREGOING INFORMATION, INCLUDING INFORMATION REQUIRED BY ITEM 7 OF SCHEDULE 14A WITH REGARD TO THE COMPANY’S NOMINEES. STOCKHOLDERS CAN ACCESS THE COMPANY’S PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS DISCLOSING THIS INFORMATION, WITHOUT COST, ON THE SEC’S WEBSITE AT WWW.SEC.GOV. The information concerning the Company contained in this Proxy Statement (including Appendix Aattached hereto) has been taken from, or is based upon, publicly available information. The SEC maintains a website that contains periodic and current reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, which are made available, free of charge, at www.sec.gov. Your vote is important. No matter how many shares of Common Stock you own, please vote to elect the Nominees by marking, signing, dating and mailing the enclosed BLUEuniversal proxy card promptly. 18 Daniel J. Mangless [●], 2025 19 APPENDIX A COMMON STOCK TRANSACTIONS IN ZEVRA THERAPEUTICS, INC. The following table sets forth information with respect to all purchases and sales of Common Stock by the Proponent during the past two years.

|